Table 1.
Summary of major recent clinical trials in transplant-eligible patients with newly diagnosed multiple myeloma.
| Ref. | Regimen | Cycle of induction | N | CR rate prior to transplant | Median PFS | Median OS |
|---|---|---|---|---|---|---|
| Cavo et al. [28] | VTD vs. | 3 | 236 | 19% | 3-year PFS; 68% | 3-year OS; 86% |
| TD | 238 | 5% | vs. 56% | vs. 84% | ||
| Rosiñol et al. [29] | VTD vs. | 6 | 130 | 35% | 56.2 mo | 4-year OS; 74% |
| TD vs. | 127 | 14% | 28.2 mo | vs. 70% | ||
| VBMCP/VBAD/B | 129 | 0.21 | 35.3 mo | vs. 65% | ||
| Moreau et al. [31] | VTD vs. | 4 | 169 | 13% | NA | NA |
| VCD | 169 | 8.9% | ||||
| Rosiñol et al. [33] | VRD | 6 | 458 | 33.4% | NA | NA |
| Moreau et al. [37] | D-VTD vs. | 4 | 543 | 39% | 18 mo PFS; 93% | NA |
| VTD | 542 | 26% | vs. 85% |
Abbreviations: CR, complete response; D-VTD; daratumumab, bortezomib, thalidomide, and dexamethasone; NA, not evaluable; OS, overall survival; PFS, progression-free survival; Ref, reference; TD, thalidomide and dexamethasone; VBMCP/VBAD, vincristine, VCD, bortezomib, cyclophosphamide, and dexamethasone; VRD, bortezomib, lenalidomide, and dexamethasone; VTD, bortezomib, thalidomide, and dexamethasone.